Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia

Mycoses

Volumn 54, Issue 4, 2011, Pages

  Illmer, Thomas ^a   Babatz, Jana ^a   Pursche, Stefan ^a   Stölzel, Friedrich ^a   Schuler, Ulrich ^a   Schaich, Markus ^a   Ehninger, Gerhard ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

ALL; Aspergillosis; Posaconazole; Prophylaxis; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; POSACONAZOLE; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IN VIVO STUDY; INFECTION PREVENTION; LIVER TOXICITY; LUNG ASPERGILLOSIS; MALE; MYCOSIS; NAUSEA; NEPHROTOXICITY; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; VOMITING;

ADULT; ALANINE TRANSAMINASE; ANTIFUNGAL AGENTS; ASPARTATE AMINOTRANSFERASES; ASPERGILLUS; BILIRUBIN; CANDIDA; CHEMOPREVENTION; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MYCOSES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRIAZOLES; YOUNG ADULT;

ASPERGILLUS; CANDIDA;

EID: 79959224002     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01860.x     Document Type: Article

References (15)

1. Hoelzer D, Gokbuget N. Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol 2002; 15: 713-28.
2. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2006; 133-41.
3. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
4. Grigull L, Beier R, Schrauder A et al. Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses 2003; 46: 441-6.
5. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356: 409-11.
6. Robenshtok E, Gafter-Gvili A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471-89.
7. Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007; 55: 287-99.
8. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-21.
9. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
10. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
11. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-9.
12. Raff T, Gokbuget N, Luschen S et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007; 109: 910-5.
13. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
14. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: e711-6.
15. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21: 645-53.